Advertisement
Advertisement
RPRX
Royalty Pharma plc Class A Ordinary Shares
57.97
USDSponsored
+1.20
+2.11%
Aug 10, 16:00 UTC -4
Closed
After-Market
58.22
+0.25
+0.43%
RPRX Earnings Reports
Positive Surprise Ratio
RPRX beat 15 of 25 last estimates.
60%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$833.86M
/$1.13
Implied change from Q2 26 (Revenue/ EPS)
+7.87%
/-14.39%
Implied change from Q3 25 (Revenue/ EPS)
+2.44%
/-3.42%
Royalty Pharma plc Class A Ordinary Shares earnings per share and revenue
On Aug 05, 2026, RPRX reported earnings of 1.32 USD per share (EPS) for Q2 26, beating the estimate of 1.30 USD, resulting in a 1.30% surprise. Revenue reached 773.00 million, compared to an expected 707.05 million, with a 9.33% difference. The market reacted with a +0.47% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of 1.13 USD, with revenue projected to reach 833.86 million USD, implying an decrease of -14.39% EPS, and increase of 7.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
MAIA Biotechnology, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-15.86%
FAQ
What were Royalty Pharma plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Royalty Pharma plc Class A Ordinary Shares reported EPS of $1.32, beating estimates by 1.3%, and revenue of $773.00M, 9.33% above expectations.
How did the market react to Royalty Pharma plc Class A Ordinary Shares's Q2 2026 earnings?
The stock price moved up 0.47%, changed from $57.48 before the earnings release to $57.75 the day after.
When is Royalty Pharma plc Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Royalty Pharma plc Class A Ordinary Shares's next earnings report?
Based on 4
analysts, Royalty Pharma plc Class A Ordinary Shares is expected to report EPS of $1.13 and revenue of $833.86M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement